IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow
Published on 09/04/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ironwood Pharmaceuticals stock (US46333X1080) is back in view on September 4, 2026, with the Nasdaq-listed company trading at USD 0.75 and a market capitalization of USD 117.8 million, according to finance data on Yahoo Finance.
The catalyst in the session is a conference appearance flagged by MarketScreener, which points to the Wells Fargo 21st Annual Healthcare Conference. For investors, the more important backdrop is still the latest reported quarter and the cash profile.
Latest quarter numbers
In the June 2026 quarter, Ironwood reported USD 27.8 million in revenue and a net loss of USD 10.2 million, according to the same-day market summary that cited the period. That compares with USD 31.0 million in revenue in the March 2026 quarter, so revenue fell by USD 3.2 million quarter over quarter.
Adjusted EBITDA was USD 4.1 million in the June 2026 quarter, while the company also carried USD 171.4 million in cash and equivalents. The numbers matter because the market is paying for execution, not just the conference calendar.
Cash and guidance
The most recent company picture also includes a forward point: management has described the business around GI therapies and a commercial base tied to constipation and IBS-C treatment, with performance still dependent on prescription trends and operating leverage. The latest figures in the public data set keep the emphasis on revenue momentum and liquidity rather than scale.
Stockwatch identified Ironwood Pharmaceuticals as a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases, which remains the commercial frame around the share. That puts every quarterly update in a narrower investor range: sales, cash and guidance.
Ironwood Pharmaceuticals corporate profile
The company links its market story to GI therapies, quarterly revenue and cash generation.
Ironswood pipeline focus
Ironwood centers on gastrointestinal medicines, and that focus makes each sales update and conference appearance more relevant than broad sector commentary. The companys market value of USD 117.8 million leaves little room for weak operating trends.
Price and venue
At USD 0.75 on September 4, 2026, the stock remains a low-priced Nasdaq issue with a small-cap profile. The combination of USD 0.75, USD 117.8 million and the June 2026 revenue base shows why traders are watching the next update closely.
Ironwood Pharmaceuticals stock facts
- Company: Ironwood Pharmaceuticals, Inc.
- ISIN: US46333X1080
- Ticker: IRWD
- Trading venue: Nasdaq
- Price (as of September 4, 2026): USD 0.75
- Market capitalization: USD 117.8 million (as of September 4, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not in a major U.S. index
